<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Leprosy: Treatment and prevention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Leprosy: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Leprosy: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Scollard, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Stryjewska, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mara Dacso, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H310299817"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Leprosy (also known Hansen's disease) is an infectious disease caused by <em>Mycobacterium leprae</em> and <em>Mycobacterium lepromatosis</em> that involves the skin and peripheral nerves [<a href="#rid1">1-3</a>].</p><p><em>M. leprae</em> and <em>M. lepromatosis</em> comprise "<em>Mycobacterium leprae</em> complex" [<a href="#rid4">4</a>]. The deoxyribonucleic acid (DNA) sequences of <em>M. leprae</em> and <em>M. lepromatosis</em> differ enough to distinguish them as separate species, but they share many similarities (both are obligate intracellular pathogens with a tropism for nerves) and cause the same clinical disease [<a href="#rid5">5</a>].</p><p>Leprosy is an important global health concern. Contrary to popular folklore, leprosy is not highly contagious, and effective treatment is available [<a href="#rid1">1,6-8</a>]. Early diagnosis and treatment are necessary to minimize the likelihood of disability involving the eyes, hands, and feet due to neuropathy, as these are often not reversible and may require lifelong care [<a href="#rid9">9</a>].</p><p>Not all patients have access to appropriate therapy, and not all countries have the infrastructure to support leprosy control efforts [<a href="#rid10">10</a>]. Worldwide, the number of dedicated leprosy programs is declining, and international migration is bringing patients to nearly every region [<a href="#rid11">11</a>].</p><p>The treatment and prevention of leprosy are reviewed here. The epidemiology, microbiology, clinical manifestations, and diagnosis of leprosy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5348.html" rel="external">"Leprosy: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H7448168"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Leprosy has been classified into the following categories based on the Ridley-Jopling classification  (<a class="graphic graphic_figure graphicRef67611" href="/z/d/graphic/67611.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculoid (TT)</p><p class="bulletIndent1"><span class="glyph">●</span>Borderline tuberculoid (BT)</p><p class="bulletIndent1"><span class="glyph">●</span>Mid-borderline (BB)</p><p class="bulletIndent1"><span class="glyph">●</span>Borderline lepromatous (BL)</p><p class="bulletIndent1"><span class="glyph">●</span>Lepromatous (LL)</p><p class="bulletIndent1"><span class="glyph">●</span>Indeterminate (I)</p><p></p><p>The classification of leprosy is discussed in further detail separately. (See  <a class="medical medical_review" href="/z/d/html/5348.html" rel="external">"Leprosy: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Classification and terminology'</a>.)</p><p class="headingAnchor" id="H310298018"><span class="h1">ANTIMICROBIAL THERAPY</span></p><p class="headingAnchor" id="H21479664"><span class="h2">General approach</span><span class="headingEndMark"> — </span>Treatment of leprosy consists of multidrug therapy (MDT) to minimize the likelihood of resistance [<a href="#rid1">1</a>]. First-line medications include <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>. These agents are effective for treatment of leprosy due to <em>M. leprae</em> and <em>M. lepromatosis</em> [<a href="#rid12">12-17</a>].</p><p>No controlled trials comparing drug combination regimens have been performed; relapse rate is an important criterion for efficacy, and evaluation of relapse rate requires a long observation period (approximately 15 to 20 years). The efficacy of the individual agents had been demonstrated clinically, in animal studies, and in vitro [<a href="#rid18">18-20</a>]. </p><p class="headingAnchor" id="H2900081115"><span class="h3">Within the United States</span><span class="headingEndMark"> — </span>Our treatment approach is in alignment with the United States National Hansen's Disease Program (NHDP), as follows  (<a class="graphic graphic_table graphicRef51183" href="/z/d/graphic/51183.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef64965" href="/z/d/graphic/64965.html" rel="external">table 2</a>) [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculoid disease (TT, BT types; the WHO refers to this as paucibacillary [PB]) – <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">Dapsone</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> for 12 months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lepromatous disease (BB, BL, LL types; the WHO refers to these as multibacillary [MB]) – <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">Dapsone</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> for 24 months</p><p></p><p>The NHDP approach follows World Health Organization (WHO) guidance issued in 1982 [<a href="#rid7">7</a>], which differs from the WHO 2018 guidelines with respect to the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Duration of therapy – The NHDP (WHO 1982) approach consists of longer duration of therapy than the WHO 2018 approach; the NHDP has maintained a conservative approach in the absence of robust data to support shortened duration of treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Frequency of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> administration – The NHDP approach consists of more frequent rifampin administration (daily rather than monthly). This approach is supported by a study including 158 patients with leprosy (123 with MB disease) treated with regimens including daily rifampin and followed for 10 to 15 years; only one case of relapse was observed (in a patient with MB disease who was treated with a two-drug regimen rather than a three-drug regimen) [<a href="#rid6">6</a>]. While this relapse rate is similar to that of the WHO, the WHO rate is based on a shorter follow-up period (5 years). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Role of <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> – The NHDP excludes clofazimine for treatment of PB disease. (See <a class="local">'Outside the United States'</a> below.)</p><p></p><p>In the United States, medication for the treatment of leprosy is provided free of charge by the NHDP (1-800-642-2477) [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H151253511"><span class="h3">Outside the United States</span><span class="headingEndMark"> — </span>The 2018 WHO guidelines treatment approach is as follows  (<a class="graphic graphic_table graphicRef51183" href="/z/d/graphic/51183.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef64965" href="/z/d/graphic/64965.html" rel="external">table 2</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculoid (TT-BT; PB) disease: <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">Dapsone</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> for 6 months.</p><p class="bulletIndent1"><span class="glyph">●</span>Lepromatous (BB-BL-LL; MB) disease: <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">Dapsone</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> for 12 months. </p><p></p><p>Compared with NHDP, use by the WHO of a shorter treatment duration and less frequent <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> administration (monthly rather than daily) partly reflects cost considerations. </p><p>Use of <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> for patients with PB disease is controversial because treatment with <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (without clofazimine) has been successful. However, it has been proposed that routine use of clofazimine reduces the likelihood of undertreating patients with MB disease who may be misclassified as having PB disease. In the United States, the classification of all cases includes histopathologic assessment of a skin biopsy, including documentation of the bacterial load, and misclassification is not an issue.  </p><p>The WHO distributes medications through the Ministry of Health in each country [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H4189689602"><span class="h2">Clinical response and follow-up</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical response</strong> – The exact time to noninfectiousness is not known since <em>M. leprae </em>cannot be cultivated; however, treatment likely renders the patient noninfectious within a few days. </p><p></p><p class="bulletIndent1">The erythema and induration of skin lesions may diminish within a few months of initiating therapy. It may take a few years for cutaneous lesions to resolve fully, depending on the initial number of lesions and severity of infection. Most lesions heal without scarring.</p><p></p><p class="bulletIndent1">Once killed, dead bacilli are removed from the tissues very slowly; some may persist in the tissues for several years  (<a class="graphic graphic_picture graphicRef74309" href="/z/d/graphic/74309.html" rel="external">picture 1</a>) [<a href="#rid22">22</a>]. Since <em>M. leprae </em>and <em>M. lepromatosis</em> cannot be grown in culture and its viability cannot be assessed in biopsies, a definitive bacteriologic endpoint for treatment is not available. The presence of bacilli in smears or biopsies during and after treatment does not, in itself, indicate treatment failure or drug resistance. There is no evidence that prolonged antimicrobial treatment enhances the removal of dead <em>M. leprae</em> from tissues.</p><p></p><p class="bulletIndent1">Given the lack of a definitive therapeutic endpoint, assessing compliance is especially important in assessing completeness of treatment. Laboratory evidence indicates that <em>M. leprae</em> are killed rapidly after exposure to <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> and the other drugs used [<a href="#rid23">23</a>]. Experience with multidrug therapy has provided good evidence of cure with very few relapses using NHDP or WHO protocols with one to two years of treatment [<a href="#rid9">9</a>]. Therefore, if adherence to the well-established MDT protocols is good, killing of the bacilli and resolution of the lesions can be expected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – While on treatment, we schedule the first follow-up in two to four weeks to evaluate for side effects of medications. After that, we schedule routine follow-up visits every three months. Visits should consist of a clinical examination, including assessment of the skin, nerves, limbs, and eyes, as well as laboratory studies to assess drug toxicity. Patients should be asked about any new skin lesions, sensory or motor loss, eye symptoms, reactions, or other complaints.</p><p></p><p class="bulletIndent1">Disease progression that occurs during therapy is almost always due to poor adherence to treatment. Therefore, patient education is an important part of each visit; compliance with a prolonged drug regimen is unlikely unless the patient fully understands the necessity for it. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hand and foot care</strong> – For areas of the hands and feet where sensation has been lost, patients need to be taught to evaluate these areas regularly for evidence of injury and to obtain treatment promptly. Special protective shoes may be needed to avoid injury or ulceration. Motor loss resulting in deformities may require corrective surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye care</strong> – Examination of the eyes should include assessment of lid closure, cornea, and conjunctiva [<a href="#rid24">24</a>]. Complex problems such as iridocyclitis should be managed by a specialist. Corneal anesthesia and lagophthalmos require protective measures and corrective surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up skin biopsies</strong> – If histopathologic follow-up evaluation is desired in lepromatous (MB) cases, we favor obtaining skin biopsies from the same lesion at one- to two-year intervals. The reduction of inflammation and the decline of bacilli in the tissues can be assessed. Processing and interpretation of biopsies for this purpose are available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hrsa.gov%2Fhansens-disease%2Fdiagnosis%2Fbiopsy&amp;token=LJaA5bS15xTkZaBw1awM27Byc%2BxDaRxLSkd8woM%2FJ90ANUFdakfSFZadL8mGDpzJnlmRdO7NNKskFTdCZNgPqw%3D%3D&amp;TOPIC_ID=16520" target="_blank">NHDP</a> at no cost.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory follow-up</strong> – Routine laboratory studies to assess drug toxicity while on treatment include a complete blood count, urinalyses, creatinine, and liver function tests  (<a class="graphic graphic_table graphicRef76797" href="/z/d/graphic/76797.html" rel="external">table 3</a>). Drug toxicity is relatively uncommon after the first year of treatment, and serious toxicity may manifest clinically before it is detected in the laboratory. Asymptomatic liver enzyme elevation of up to three times normal is acceptable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>After completion of treatment</strong> – After completion of treatment, annual follow-up for three more years is warranted for patients with tuberculoid disease, and annual follow-up for five more years is warranted for patients with lepromatous disease. Patients should be advised to return for evaluation if new lesions or other problems develop.</p><p></p><p class="headingAnchor" id="H2695870956"><span class="h2">Adverse effects of antimicrobial agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dapsone</strong> – <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">Dapsone</a> is generally well tolerated in the doses used for the treatment of leprosy. Adverse effects include dapsone hypersensitivity syndrome, methemoglobinemia, and agranulocytosis. Shortened red cell survival is common with dapsone, though severe hemolytic anemia is uncommon except in those with a severe glucose-6-phosphate dehydrogenase (G6PD) deficiency; all patients should be screened for G6PD deficiency before receiving dapsone. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia"</a> and  <a class="medical medical_review" href="/z/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis"</a> and  <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">"Drug-induced hemolytic anemia"</a>.)</p><p></p><p class="bulletIndent1">Quantitative G6PD assays discriminate intermediate levels with greater accuracy than qualitative assays [<a href="#rid25">25</a>]. Qualitative tests can identify severe deficiencies but do not identify intermediate levels as effectively, and therefore, the results should be interpreted cautiously [<a href="#rid25">25</a>]. A normal result (absence of G6PD deficiency) for adults ranges 7 to 20.5 units/gram of hemoglobin and depends on gender, pregnancy status, biogenetics, and other factors [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent1">Patients with severe deficiency (&lt;10 percent normal) should not be treated with <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> due to risk of severe hemolytic anemia. Patients with moderate deficiency (10 to 60 percent of normal range) may have intermittent hemolytic anemia if treated with dapsone; if dapsone must be used in such cases, close clinical monitoring with serial blood count measurements is warranted. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rifampin</strong> – <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> is the most bactericidal drug that is routinely used for the treatment of leprosy. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">Rifampin</a> toxicity correlates with the dose and the interval between doses. The standard doses for leprosy are relatively nontoxic; occasional cases of renal failure, bone marrow suppression, "flu-like" syndrome, and hepatitis have been reported. </p><p></p><p class="bulletIndent1">Daily administration of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> has major effects on drug metabolism by the liver cytochrome 3A4 (CYP3A4), which greatly affects other medications such as oral contraceptives, corticosteroids, and human immunodeficiency virus (HIV) protease inhibitors, among many others. (See  <a class="medical medical_review" href="/z/d/html/491.html" rel="external">"Rifamycins (rifampin, rifabutin, rifapentine)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clofazimine</strong> – <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">Clofazimine</a> is not available in pharmacies in the United States. It is classified by the US Food and Drug Administration (FDA) as an investigational drug. Requests for clofazimine to treat leprosy should be directed to the NHDP (an agency within the Department of Health and Human Services), which holds the investigational new drug protocol for this indication, at 1-800-642-2477 (phone) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">Clofazimine</a> is weakly bactericidal against <em>M. leprae</em>, but the combination of clofazimine and <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> is much more active than either drug alone, killing 99.999 percent of bacilli in mouse studies within three months [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">The major adverse effect of <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> is skin pigmentation (especially within skin lesions) since the drug is lipophilic and accumulates in the lipid-rich cell wall <em>of M. leprae</em>. At higher doses (200 mg daily), hyperpigmentation may be noticeable within four weeks; at lower doses, it may take four to six months. Clofazimine causes phototoxicity, which can accelerate darkening of the skin with sun exposure. This pigmentation usually clears within one to two years after treatment is discontinued. Some patients are reluctant to take clofazimine because of the pigmentation but will usually accept it if the temporary nature of the pigmentation and the benefit of reducing the likelihood of a debilitating treatment reaction are carefully explained. </p><p></p><p class="bulletIndent1">The higher doses of <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> (up to 300 mg daily) sometimes used for the control of immunologic reactions may occasionally produce gastrointestinal side effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative agents </strong>– The following agents are bactericidal for <em>M. leprae</em> and may be used if the standard agents are contraindicated. However, they have not been evaluated in adequately powered clinical trials; they should be used in consultation with clinicians who experienced with treatment of leprosy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Minocycline</strong> – <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> is the only <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> with significant activity against <em>M. leprae</em>. This may be due to its lipophilic properties, which allow the drug to penetrate cell walls. It is bactericidal for <em>M. leprae</em> to a somewhat greater degree than <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> but much less so than <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>. </p><p></p><p class="bulletIndent2">Side effects of <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> include teeth discoloration in children, occasional pigmentation of the skin and mucous membranes, gastrointestinal complaints, and central nervous system toxicity including dizziness and unsteadiness.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clarithromycin</strong> – Several macrolides have been evaluated for activity against <em>M. leprae</em>; <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> is the only effective agent. Clarithromycin has potent bactericidal activity but is less bactericidal than <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>. At a dose of 500 mg daily, 99 percent of <em>M. leprae</em> are killed in 28 days and 99.9 percent by 56 days [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent2">Gastrointestinal irritation, nausea, vomiting, and diarrhea are the most common adverse effects, but they do not usually necessitate drug discontinuation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fluoroquinolones</strong> – Fluoroquinolones with activity against leprosy include <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">ofloxacin</a>, <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, and <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>. Adverse effects of fluoroquinolones are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/490.html" rel="external">"Fluoroquinolones"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">Ofloxacin</a> – Ofloxacin has good antibacterial activity and is the most widely accepted fluoroquinolone for treatment of leprosy [<a href="#rid28">28</a>]. It acts by interfering with bacterial DNA replication by inhibiting the A subunit of the DNA gyrase. A single 400 mg dose has bactericidal activity again<em>st M. leprae</em>, although less than that demonstrated by a single dose of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and two doses are capable of killing 99.99 percent of the viab<em>le M. leprae</em>. <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">Levofloxacin</a>, the active L-racemer of ofloxacin, has replaced ofloxacin in many United States formularies. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">Moxifloxacin</a> – Moxifloxacin is also highly bactericidal against <em>M. leprae</em>; further study of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> and moxifloxacin as combination short-term therapy is needed [<a href="#rid30">30,31</a>]. </p><p></p><p class="headingAnchor" id="H310298161"><span class="h1">IMMUNOLOGIC REACTIONS AND NEURITIS</span></p><p class="headingAnchor" id="H2663194626"><span class="h2">Immunologic reactions</span></p><p class="headingAnchor" id="H3431375473"><span class="h3">General principles</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Immunologic reactions are systemic inflammatory complications that occur either before treatment (some patients initially present for medical attention in the setting of a reaction), during treatment, or months to years after treatment has been completed [<a href="#rid32">32</a>]. Clinical manifestations may include fatigue, malaise, fever, neuritis (nerve enlargement, tenderness, or loss of function), arthritis, iritis, and nasopharyngeal symptoms. The associated inflammation can lead to severe nerve injury with subsequent paralysis and deformity. </p><p></p><p class="bulletIndent1">Immunologic reactions are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/5348.html" rel="external">"Leprosy: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Immunologic reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distinguishing immunologic reactions from other entities</strong> – For patients on appropriate antimicrobial therapy, the most common cause of disease progression is inadequate adherence. Other less common considerations include relapse or drug resistance. (See <a class="local">'New skin lesions during or after treatment'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuation of antimicrobial therapy</strong> – Antimicrobial therapy should be continued in the setting of immunologic reactions, and patients should be reassured that the symptoms are not a reaction to the medications. </p><p></p><p class="headingAnchor" id="H2781552"><span class="h3">Type 1 reaction (T1R, reversal reaction)</span><span class="headingEndMark"> — </span>T1R typically occurs in patients with borderline tuberculoid (BT), mid-borderline (BB), or borderline lepromatous (BL) disease. Clinical manifestations of T1R are described separately. (See  <a class="medical medical_review" href="/z/d/html/5348.html" rel="external">"Leprosy: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Type 1 reaction (T1R, reversal reaction)'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild reactions</strong> – Mild reactions (edema and erythema of existing skin lesions, in the absence of neuritis [nerve enlargement, tenderness, or loss of function] or skin ulceration) may be managed with analgesics such as nonsteroidal anti-inflammatory drugs [<a href="#rid11">11</a>]. Such patients must be observed closely for deterioration of nerve function, which requires more aggressive treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe reactions</strong> – Severe reactions (including neuritis [nerve enlargement, tenderness, or loss of function], skin ulceration, fever, and/or joint pain) warrant prompt treatment to avoid permanent nerve damage [<a href="#rid33">33</a>]. The mainstay of treatment consists of corticosteroids; potential alternative agents include <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Corticosteroids</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Clinical approach</strong> – There is no consensus on the optimal dose or duration of corticosteroids for treatment of immunologic reactions [<a href="#rid34">34</a>]. Our approach consists of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 60 mg daily (maximum 1 mg/kg); the duration is typically at least 12 weeks (or longer, depending on individual circumstances) followed by a taper, depending on the severity of the reaction and the response to treatment. Rapid improvement of nerve function occurs most often in situations when the lesion is of recent onset (less than six months).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Rifampin</strong><strong> dose adjustment</strong> – Coadministration of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> accelerates metabolism of prednisone; for patients receiving prednisone, we reduce the rifampin dose from 600 mg daily to 600 mg monthly. After prednisone has been discontinued, daily rifampin should be resumed.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Efficacy</strong> – The benefit of steroids is uncertain. In a 2016 review [<a href="#rid35">35</a>], moderate-quality evidence from two randomized trials including 179 patients with longstanding or mild nerve function impairment demonstrated no superior effect of corticosteroids over placebo with respect to nerve function improvement; however, a third trial including 334 patients with T1R demonstrated benefit from a 20-week steroid regimen over a 12-week regimen; at the end of 12 months, additional steroid treatment was required more frequently among patients who received the shorter course (46 versus 31 percent) [<a href="#rid36">36</a>]. In a subsequent randomized trial including more than 800 patients with leprosy and nerve function impairment, the efficacy of a 20-week <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> course was comparable to that of a 32-week course for improving or restoring nerve function (78 percent) [<a href="#rid37">37</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adverse effects</strong> – Prolonged use of corticosteroids entails the risk of many serious side effects. If prolonged therapy will be needed, switching to an every-other-day schedule may reduce the risk of side effects [<a href="#rid38">38</a>]. For patients receiving ≥20 mg of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> daily for one month or longer, initiation of prophylaxis for prevention of <em>Pneumocystis</em> warrants consideration. (See  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No role for prophylaxis</strong> – No long-term benefit has been associated with prophylactic corticosteroid treatment for prevention nerve function impairment. </p><p></p><p class="bulletIndent3">In a randomized trial including 636 patients with newly diagnosed multibacillary (MB) leprosy, patients were randomly assigned to receive antimicrobial therapy with or without <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> (20 mg/day for three months, followed by taper). Those who did not receive <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> had a higher likelihood of nerve function impairment at four months (15 versus 4 percent; relative risk 3.9, 95% CI 2.1 to 7.3); however, the benefit was not maintained at one year (relative risk 1.3, 0.9 to 1.8) [<a href="#rid39">39</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other agents</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Cyclosporine</strong> – <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> may be a useful second-line treatment for severe T1R in patients who do not respond to or who are unable to take corticosteroids [<a href="#rid40">40</a>]. It has been demonstrated to improve sensory nerve impairment and skin lesions in small numbers of patients in Brazil, Ethiopia, and Nepal [<a href="#rid41">41,42</a>]. Further study is needed to determine optimal dosing and to compare efficacy and toxicity with corticosteroids.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Methotrexate</strong> – In patients with concomitant diabetes, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> is a potential steroid sparing regimen; further study is needed [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H310298210"><span class="h3">Type 2 reaction (T2R, erythema nodosum leprosum [ENL])</span><span class="headingEndMark"> — </span>T2R occurs in patients with BL and lepromatous (LL) disease. Clinical manifestations of T2R are described separately. (See  <a class="medical medical_review" href="/z/d/html/5348.html" rel="external">"Leprosy: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Type 2 reaction (T2R, erythema nodosum leprosum, ENL)'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild reactions</strong> – Mild reactions (low-grade fever, mild skin lesions, mild nerve pain without loss of function) may be managed with analgesics such as nonsteroidal anti-inflammatory drugs [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe reactions</strong> – Severe reactions (including fever, neuritis [nerve pain, tenderness, or loss nerve function], skin ulceration, loss of sensation or muscle weakness [hands, feet, or eyes], joint pain, eye pain and redness [uveitis, scleritis], and/or headache) warrant prompt treatment to avoid permanent nerve damage. </p><p></p><p class="bulletIndent1">The mainstay of T2R treatment consists of corticosteroids; in addition, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> is a favored drug for treatment of T2R in areas where available. Alternative approaches include <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>, or tumor necrosis factor-alpha (TNF-a) inhibitors. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Use of corticosteroids</strong> – Use corticosteroids for treatment of T2R is as discussed above for T1R. (See <a class="local">'Type 1 reaction (T1R, reversal reaction)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other agents</strong> – Other immunosuppressive drugs have been evaluated for management of T2Rs [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Thalidomide</strong> – <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a> is a favored drug for treatment of T2R in areas where available [<a href="#rid34">34</a>], but teratogenicity limits its use in women of childbearing age. Thalidomide is typically used for situations in which <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> is not effective for controlling the reaction or in which use of prednisone is precluded by adverse effects. There has been no rigorous comparison of clinical efficacy between thalidomide and prednisone; in one study including 30 patients with erythema nodosum leprosum (ENL), thalidomide enabled weaning off of steroids over a median of two months in 75 percent of cases [<a href="#rid44">44</a>]. </p><p></p><p class="bulletIndent3">Our approach consists of initial treatment with 200 to 400 mg daily; frequently, this regimen controls the reaction within 48 hours. Subsequently, we taper the dose to a maintenance level, generally around 100 mg daily. <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a> may be continued for several years to control ENL; every few months, we attempt to taper off the drug. In our experience, a few patients with severe, prolonged T2Rs have continued use of thalidomide for up to 10 years. </p><p></p><p class="bulletIndent3">Development of symmetrical painful paresthesia of the hands and feet and sensory loss in lower extremities should prompt discontinuation of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>. </p><p></p><p class="bulletIndent3">In a retrospective review including 102 patients with ENL treated with <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, improvement was observed in 67 percent of cases; recurrence occurred in 16 percent with a mean duration of 14 months [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent3">In the United States, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> is approved for marketing only under a special restricted distribution program approved by the US Food and Drug Administration (FDA) called "Risk Evaluation and Management Strategy" (REMS). Under this program, only prescribers and pharmacists registered with the program are allowed to prescribe and dispense the product. In addition, patients must be advised of, agree to, and comply with the requirements of the REMS program in order to receive the drug.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Methotrexate</strong> – For patients with ENL and neuropathy (loss of protective sensation in at least one limb) who are unable to tolerate high-dose steroids, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (10 to 25 mg weekly) with or without low-dose corticosteroids (1 to 7.5 mg daily) is a potential alternative regimen [<a href="#rid43">43,46,47</a>]. The duration of treatment may range from 12 to 24 months, guided by individual status of the peripheral neuropathy. Further study of methotrexate for management of leprosy reactions is ongoing [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent3">Patients treated with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> should have baseline laboratory testing and receive coadministration of folate; these issues are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate"</a> and  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Prevention of side effects with folate'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Clofazimine</strong> – <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">Clofazimine</a> is not useful for the management of acute T2R but may be used as an alternative regimen for chronic T2R in patients who are unable to be treated with high-dose corticosteroids [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent3"><a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">Clofazimine</a> may be increased to a dose of 300 mg daily for four weeks and tapered slowly after response to 100 mg/day within 12 months. Gastrointestinal complaints may limit the use of higher doses. </p><p></p><p class="bulletIndent3">The <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> component of the MB regimen may have some protective effect in preventing reactions since T2R appears to have become less common with inclusion of this agent in treatment regimen. </p><p></p><p class="bulletIndent3">In the United States <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> can be obtained through the National Hansen's Disease Program (NHDP; phone 1-800-642-2477).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>TNF-a inhibitors</strong> – In the most intractable cases, anti-TNF agents have been employed [<a href="#rid50">50</a>], but this is advisable only after the patient has completed a full course of multidrug therapy (MDT).</p><p></p><p class="bulletIndent3">Successful use of TNF-a inhibitors for management of rare cases of severe T2R has been described; however, these agents should be used cautiously and with close monitoring. In one review, use of TNF-a inhibitors was successful for treatment of four patients with intractable T2R; however, among 10 patients with arthritis or other conditions treated with TNF-a inhibitors, use of these agents was a risk factor for development of leprosy [<a href="#rid51">51</a>]. In addition, we are aware of unpublished cases in which use of these agents was not successful for management of T2R [<a href="#rid52">52</a>]. </p><p></p><p class="headingAnchor" id="H2814056969"><span class="h3">Lucio phenomenon</span><span class="headingEndMark"> — </span>Lucio phenomenon (necrotizing vasculopathy in patients with longstanding untreated lepromatous leprosy) is a rare but severe and potentially life-threatening reaction. Management requires antimicrobial therapy and corticosteroids as well as skin and wound care comparable with that given for extensive burns [<a href="#rid53">53</a>]. Such patients should be managed in consultation with a clinician experienced with the treatment of Lucio reactions.</p><p class="headingAnchor" id="H2555337706"><span class="h2">Neuritis</span><span class="headingEndMark"> — </span>Some patients have progressive sensory or motor loss in hands or feet in the absence of nerve pain or other signs of immunologic reaction. For patients with deteriorating nerve function for less than six months who are adherent to antimicrobial treatment, we favor treatment with corticosteroids. The approach is as discussed above for treatment of immunologic reactions. (See <a class="local">'Type 1 reaction (T1R, reversal reaction)'</a> above.)</p><p>Neuritis may persist for months or years; there are no rigorous data on its responsiveness to treatment [<a href="#rid32">32</a>]. </p><p class="headingAnchor" id="H3344185713"><span class="h1">OTHER MANAGEMENT ISSUES</span></p><p class="headingAnchor" id="H1605683535"><span class="h2">New skin lesions during or after treatment</span><span class="headingEndMark"> — </span>The development of new lesions during or after completion of treatment is usually attributable to an immunologic reaction (see <a class="local">'Immunologic reactions and neuritis'</a> above); less common causes include disease relapse and drug resistance. (See <a class="local">'Relapse'</a> below and <a class="local">'Drug resistance'</a> below.)</p><p>During treatment, baseline skin lesions may remain unchanged or appear to worsen, with erythema and swelling. Development of new skin lesions almost always reflects an immunologic reaction. </p><p class="headingAnchor" id="H1681626263"><span class="h3">Clinical approach</span><span class="headingEndMark"> — </span>The characteristic clinical features are usually sufficient to make the diagnosis of an immunologic reaction. If there is uncertainty about the diagnosis, a biopsy may be helpful. Polymorphonuclear leukocytes are a hallmark of type 2 reactions (T2Rs); no reliable histologic criteria have been identified for type 1 reactions (T1Rs), so this remains a clinical diagnosis. (See  <a class="medical medical_review" href="/z/d/html/5348.html" rel="external">"Leprosy: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Skin biopsy'</a>.)</p><p>If the new lesion is consistent with an immunologic reaction, we typically begin with a <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> challenge (20 to 60 mg/day for seven days), followed by reassessment [<a href="#rid3">3</a>]; for patients who respond clinically, we continue treatment with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (as a steroid-sparing agent) for six months.</p><p>If a relapse is suspected, a biopsy should be obtained; in addition, polymerase chain reaction (PCR) of biopsy tissue may be performed for detection of mutations associated with drug resistance. </p><p class="headingAnchor" id="H1118722279"><span class="h3">Relapse</span><span class="headingEndMark"> — </span>Most relapses occur 5 to 10 years or more after completion of treatment [<a href="#rid54">54</a>]. The World Health Organization (WHO) estimated relapse rates at nine years following multidrug therapy for multibacillary (MB) and paucibacillary (PB) leprosy are 0.77 and 1.07 percent, respectively [<a href="#rid34">34</a>]. Risk factors for relapse include incomplete treatment and very high bacterial load at the onset of treatment [<a href="#rid55">55</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – If a relapse is suspected, a biopsy should be obtained. During treatment, the tissue bacterial load falls to zero slowly (over a period of years). The bacterial load in a biopsy or skin smear may be expressed as a bacteriologic index (BI), which is the number of bacilli per 100x field, expressed as a logarithmic scale (over 1000 bacilli per average field = 6+; 100 to 1000 bacilli = 5+, etc) [<a href="#rid56">56</a>]. In relapse, the BI rises again. An increase in from 0 to 2 or more indicates probable relapse [<a href="#rid57">57</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The optimal approach to treatment of relapse is uncertain. In general, treatment consists of restarting the same regimen used for initial therapy [<a href="#rid57">57</a>]. Patients who presented initially with PB disease but relapse with MB leprosy should be retreated with a MB regimen. </p><p></p><p class="bulletIndent1">Drug resistance is extremely unlikely to have developed as long as the original<em> M. leprae</em> strain was fully sensitive to the drugs used. For patients with lack of clinical response, or relapse, testing for mutations can be done from paraffin-embedded tissues obtained prior to treatment and at the time of suspected relapse or resistance. </p><p></p><p class="headingAnchor" id="H2744284183"><span class="h3">Drug resistance</span><span class="headingEndMark"> — </span>Drug resistance in leprosy is relatively uncommon [<a href="#rid58">58</a>]. In a WHO surveillance study that evaluated the rate of <em>M. leprae </em>antimicrobial resistance among more than 1900 patients in 19 countries between 2009 and 2015, the overall rates of resistance were: <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (3.8 percent), <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> (5.3 percent), and <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">ofloxacin</a> (1.3 percent) [<a href="#rid59">59</a>]. The rate of rifampin resistance in new cases was 2 percent and in relapsed cases was 5 percent. The rate of rifampin resistance was highest among new cases in Brazil and India (15 and 8 percent, respectively) and among relapsed cases in Colombia and Mozambique (24 and 20 percent, respectively). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – For patients who do not respond to treatment for an immunologic reaction (with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> challenge), we pursue biopsy with PCR to evaluate for mutations associated with drug resistance. </p><p></p><p class="bulletIndent1">In the United States, the Molecular Biology Laboratory of the National Hansen's Disease Program (NHDP) provides testing for drug resistance mutations on all biopsies received. In other settings, if clinical and laboratory evidence suggest relapse, testing for drug resistance should be performed on a biopsy of the new lesion in order to determine appropriate agents for retreatment [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Alternative agents for treatment of leprosy include <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, and fluoroquinolones (<a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">ofloxacin</a>, <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, and <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>); their use for treatment of leprosy has not been evaluated in controlled trials. </p><p></p><p class="bulletIndent1">We are in agreement with the WHO guidelines for treatment of drug-resistant leprosy, as follows  (<a class="graphic graphic_table graphicRef141110" href="/z/d/graphic/141110.html" rel="external">table 4</a>) [<a href="#rid1">1,3</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients whose isolate demonstrates rifampicin resistance may be treated using at least two of the following second-line drugs: <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, or a fluoroquinolone (<a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">ofloxacin</a>, <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, or <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>) plus <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> daily for 6 months, followed by clofazimine plus one of the second-line drugs daily for an additional 18 months. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients whose isolate demonstrates resistance to both rifampicin and fluoroquinolones may be treated with the following drugs: <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, and <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> for 6 months followed by clarithromycin or minocycline plus clofazimine for an additional 18 months. </p><p></p><p class="headingAnchor" id="H2779411"><span class="h2">Patients with HIV infection</span><span class="headingEndMark"> — </span>There has been no increase in leprosy in regions where HIV is prevalent. In patients coinfected with <em>M. leprae</em> and HIV, initiation of antiretroviral therapy may trigger a type 1 reaction (T1R); this is a manifestation of the immune reconstitution inflammatory syndrome [<a href="#rid60">60-62</a>]. (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p>The response to leprosy treatment in individuals with HIV infection appears to be comparable with the response in individuals without HIV infection [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H2779418"><span class="h2">Pregnant patients</span><span class="headingEndMark"> — </span>Immunologic reactions occur more frequently in pregnant and postpartum patients than in nonpregnant patients [<a href="#rid63">63-65</a>]. In two small series, such reactions were observed in up to 38 percent of patients [<a href="#rid66">66,67</a>]. T2Rs were observed more frequently during pregnancy; T1Rs were observed more frequently in the postpartum period.</p><p>Management of leprosy and immunologic reactions in pregnancy is the same as described above for other patients. Regimens of all medications must be modified appropriately if the mother is breastfeeding. (See <a class="local">'Antimicrobial therapy'</a> above.)</p><p class="headingAnchor" id="H310298245"><span class="h1">PREVENTION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Control measures for leprosy include clinical management of active cases as well as contact management. Household contacts should be evaluated annually for evidence of disease for at least five years and should be educated to seek immediate attention if skin or neurologic manifestations develop.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylaxis</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Household contacts</strong> – Leprosy household contacts are generally defined as<strong> </strong>persons living in the same dwelling or sharing the same kitchen as the index case. These include family members but also domestic staff, aids, co-workers, or others sharing the same accommodation. A family member living elsewhere should not be considered as a contact [<a href="#rid68">68-70</a>]. In some studies a household contact has been defined more precisely as a person living in the same house as a patient with leprosy for a cumulative total of at least six months, within the period from six years before diagnosis to one month after initiation of multidrug therapy in the patient [<a href="#rid68">68,69</a>]. </p><p></p><p class="bulletIndent2">For household contacts of patients with leprosy, we favor postexposure prophylaxis with <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">rifapentine</a>; dosing is outlined in the table  (<a class="graphic graphic_table graphicRef141107" href="/z/d/graphic/141107.html" rel="external">table 5</a>). For household contacts &lt;10 years of age, we monitor clinically for signs of <em>M. leprae</em> infection.  </p><p></p><p class="bulletIndent2">This approach is supported by a cluster-randomized trial including 7450 household contacts (≥10 years of age) of patients with newly diagnosed leprosy in China treated with <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">rifapentine</a> (single dose), <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> (single dose), or no intervention, the incidence (intention-to-treat analysis) of new leprosy cases over four-year follow-up was lower in the rifapentine group than the control group (0.09 versus 0.55 percent; incidence ratio 0.16, multiplicity-adjusted 95% CI 0.03-0.87); the cumulative incidence did not differ significantly between the rifampin group and the control group [<a href="#rid68">68</a>]. The benefit of rifapentine was observed through all four years of follow-up.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Social contacts </strong>– A social contact is defined by the WHO as an individual who has been exposed to a patient with infectious leprosy for at least 20 hours per week for at least three months per year; this may include neighbors and associates at work or school [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent2">For social contacts of patients with leprosy, we are in agreement with the WHO recommendation to use a single dose of <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> for adults and children ≥2 years of age  (<a class="graphic graphic_table graphicRef141107" href="/z/d/graphic/141107.html" rel="external">table 5</a>) [<a href="#rid1">1</a>]. For children &lt;2 years of age, we monitor clinically for signs of <em>M. leprae</em> infection.</p><p></p><p class="bulletIndent2">This approach was evaluated in a cluster-randomized controlled trial including more than 28,000 contacts of 1037 patients with newly diagnosed leprosy in Bangladesh treated with single-dose rifampicin or placebo; the protective effect was 57 percent (95% CI 33-72 percent) and lasted only for two years [<a href="#rid71">71</a>]. However, the least benefit was observed among household contacts (the participants at highest risk). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination</strong> – Vaccination with Bacillus Calmette-Guérin (BCG) is partially protective for leprosy; a single dose appears to be 50 percent protective, and two doses further increase protection [<a href="#rid72">72,73</a>]. BCG is administered at birth in most countries with high rates of leprosy; vaccination for prevention of leprosy in other regions is not economically feasible except in areas with an extremely high incidence of the disease [<a href="#rid74">74</a>]. </p><p></p><p class="bulletIndent1">Development of an improved <a class="drug drug_general" data-topicid="102736" href="/z/d/drug information/102736.html" rel="external">BCG vaccine</a>, BCG booster, or alternate vaccine strain is an important research goal that could benefit control of both tuberculosis and leprosy. Skin test antigen studies and the identification of the appropriate protective<em> M. leprae</em> genomic DNA sequence could also lead to an improved vaccine for leprosy [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H233443647"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/127439.html" rel="external">"Society guideline links: Leprosy"</a>.)</p><p class="headingAnchor" id="H89888451"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Leprosy (also known Hansen's disease) is an infectious disease caused by <em>Mycobacterium leprae</em> that involves the skin and peripheral nerves. Classification is summarized in the table  (<a class="graphic graphic_figure graphicRef67611" href="/z/d/graphic/67611.html" rel="external">figure 1</a>). Leprosy is an important global health concern; early diagnosis and treatment are important for preventing neuropathy and disability. (See <a class="local">'Introduction'</a> above and <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Within the United States</strong> – Within the United States, our approach to treatment of leprosy aligns with the United States National Hansen's Disease Program (NHDP), as follows  (<a class="graphic graphic_table graphicRef51183" href="/z/d/graphic/51183.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef64965" href="/z/d/graphic/64965.html" rel="external">table 2</a>) (see <a class="local">'Within the United States'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with tuberculoid (paucibacillary [PB]; TT, BT) disease, we suggest treatment with <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> and rifampicin for 12 months (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with lepromatous (multibacillary [MB]; LL, BL, BB) disease, we suggest treatment with <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, rifampicin, and <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> for 24 months (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Outside the United States</strong> – Outside the United States, we are in agreement with the 2018 World Health Organization (WHO) approach, as follows  (<a class="graphic graphic_table graphicRef51183" href="/z/d/graphic/51183.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef64965" href="/z/d/graphic/64965.html" rel="external">table 2</a>) (see <a class="local">'Outside the United States'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with tuberculoid (PB; TT, BT) disease, we suggest treatment with <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> for 6 months (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with lepromatous (MB; LL, BL, BB) disease, we suggest treatment with <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> for 12 months (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2">Use of a shorter treatment duration and less frequent <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> administration partly reflects cost considerations. In addition, it has been proposed that routine use of <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a> reduces the likelihood of undertreating patients with MB disease who may be misclassified as having PB disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring and follow up</strong> – During antimicrobial treatment, we schedule routine follow up every three months. Visits should include clinical examination (including assessment of the skin, nerves, limbs, and eyes) as well as laboratory studies to evaluate for drug toxicity. Patient education is important; disease progression during treatment is almost always due to poor adherence. (See <a class="local">'Clinical response and follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunologic reactions</strong> – Immunologic reactions are systemic inflammatory complications that occur before, during, or after antimicrobial treatment of leprosy. (See <a class="local">'Immunologic reactions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical approach</strong> – Mild reactions without neuritis or skin ulceration can be managed with supportive care. For patients with severe reactions with neuritis, we suggest treatment with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>); the optimal dose and duration are uncertain and should be individualized. In addition, in regions where available, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> is a favored drug for treatment of type 2 reaction (T2R), but teratogenicity limits its use in women of childbearing age. Other agents for treatment of immunologic agents are discussed above. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Continuation of antimicrobial therapy</strong> – Antimicrobial therapy should be continued in the setting of immunologic reactions, and patients should be reassured that the symptoms are not a reaction to the medications. During <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> administration, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> should be administered once monthly. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuritis</strong> – For patients with deteriorating nerve function for less than six months who are adherent to antimicrobial treatment, we suggest treatment with corticosteroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>); the optimal dose and duration are uncertain and should be individualized. (See <a class="local">'Neuritis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>New skin lesions during or after treatment</strong> – The development of new lesions during or after completion of treatment is usually attributable to an immunologic reaction; less common causes include disease relapse and drug resistance. If there is uncertainty about the diagnosis, a biopsy is useful for diagnosis of T2R as well as detection of drug resistance mutations. For patients with a suspected immunologic reaction, we suggest a trial of steroids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with relapse, management consists of retreatment with multidrug therapy (MDT; substituting alternative drugs for any of those to which resistance has been identified). (See <a class="local">'New skin lesions during or after treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prophylaxis</strong> – For household contacts of patients with leprosy, we suggest postexposure prophylaxis with <a class="drug drug_general" data-topicid="10079" href="/z/d/drug information/10079.html" rel="external">rifapentine</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>); <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> may be used as an alternative agent  (<a class="graphic graphic_table graphicRef141107" href="/z/d/graphic/141107.html" rel="external">table 5</a>). Prophylaxis is also appropriate for social contacts. Contacts who are not treated should be monitored for signs of infection. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vaccination</strong> – Vaccination with Bacillus Calmette-Guérin (BCG) is partially protective for leprosy. (See <a class="local">'Prevention'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy. https://apps.who.int/iris/bitstream/handle/10665/274127/9789290226383-eng.pdf?ua=1 (Accessed on June 10, 2020).</li><li class="breakAll">NHDP Guide to the Management of Hansen's disease https://www.hrsa.gov/sites/default/files/hrsa/hansens-disease/hansens-disease-guide-management.pdf.</li><li class="breakAll">World Health Organization. Leprosy/Hansen Disease: Management of reactions and prevention of disabilities, Dr E. A. Cooreman (Ed), WHO Technical Guidance, 2020.</li><li><a class="nounderline abstract_t">Singh P, Benjak A, Schuenemann VJ, et al. Insight into the evolution and origin of leprosy bacilli from the genome sequence of Mycobacterium lepromatosis. Proc Natl Acad Sci U S A 2015; 112:4459.</a></li><li><a class="nounderline abstract_t">Han XY, Sizer KC, Thompson EJ, et al. Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis. J Bacteriol 2009; 191:6067.</a></li><li><a class="nounderline abstract_t">Dacso MM, Jacobson RR, Scollard DM, et al. Evaluation of multi-drug therapy for leprosy in the United States using daily rifampin. South Med J 2011; 104:689.</a></li><li><a class="nounderline abstract_t">Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser 1982; 675:1.</a></li><li class="breakAll">WHO Expert Committee on Leprosy. WHO Expert Committee on Leprosy: Seventh Report. WHO Tech Rep Ser 874; Geneva, 1998.</li><li><a class="nounderline abstract_t">Global leprosy situation, 2010. Wkly Epidemiol Rec 2010; 85:337.</a></li><li><a class="nounderline abstract_t">Leprosy. Global target attained. Wkly Epidemiol Rec 2001; 76:155.</a></li><li class="breakAll">Health Resources and Services Administration. National Hansen's Disease (Leprosy) Program: Caring and Curing Since 1894. http://www.hrsa.gov/hansensdisease/ (Accessed on June 20, 2011).</li><li class="breakAll">World Health Organization. Expert Committee on Leprosy. Seventh Report. WHO, Geneva 1998.</li><li><a class="nounderline abstract_t">Ji B. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. Lepr Rev 1998; 69:106.</a></li><li><a class="nounderline abstract_t">Freerksen E, Rosenfeld M, Depasquale G, et al. The Malta Project--a country freed itself of leprosy. A 27-year progress study (1972-1999) of the first successful eradication of leprosy. Chemotherapy 2001; 47:309.</a></li><li><a class="nounderline abstract_t">Sotiriou MC, Stryjewska BM, Hill C. Two Cases of Leprosy in Siblings Caused by Mycobacterium lepromatosis and Review of the Literature. Am J Trop Med Hyg 2016; 95:522.</a></li><li><a class="nounderline abstract_t">Scollard DM. Infection with Mycobacterium lepromatosis. Am J Trop Med Hyg 2016; 95:500.</a></li><li class="breakAll">Singh P, Tufariello J, Wattam AR, et al. Genomic insights into the biology and evolution of leprosy bacilli. In Scollard DM, Gillis TP (Eds). International Textbook of Leprosy. http://www.internationaltextbookofleprosy.org/ (Accessed on November 28, 2023).</li><li><a class="nounderline abstract_t">Levy L, Ng H, Evans MJ, Krahenbuhl JL. Susceptibility of thymectomized and irradiated mice to challenge with several organisms and the effect of dapsone on infection with Mycobacterium leprae. Infect Immun 1975; 11:1122.</a></li><li><a class="nounderline abstract_t">Holmes IB, Banerjee DK, Hilson GR. Effect of rifampin, clofazimine, and B1912 on the viability of Mycobacterium leprae in established mouse footpad infection. Proc Soc Exp Biol Med 1976; 151:637.</a></li><li><a class="nounderline abstract_t">Franzblau SG. Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system. Antimicrob Agents Chemother 1989; 33:2115.</a></li><li class="breakAll">World Health Organization - Leprosy Today http://www.who.int/lep/en/ (Accessed on July 27, 2020).</li><li><a class="nounderline abstract_t">Katoch K, Natarajan M, Bagga A, Katoch VM. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT. Int J Lepr Other Mycobact Dis 1991; 59:248.</a></li><li><a class="nounderline abstract_t">Franzblau SG. In vitro activities of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae. Antimicrob Agents Chemother 1991; 35:1232.</a></li><li><a class="nounderline abstract_t">Daniel E, Ffytche TJ, Kempen JH, et al. Incidence of ocular complications in patients with multibacillary leprosy after completion of a 2 year course of multidrug therapy. Br J Ophthalmol 2006; 90:949.</a></li><li><a class="nounderline abstract_t">LaRue N, Kahn M, Murray M, et al. Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency. Am J Trop Med Hyg 2014; 91:854.</a></li><li><a class="nounderline abstract_t">Pfeffer DA, Satyagraha AW, Sadhewa A, et al. Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis. Pathogens 2022; 11.</a></li><li class="breakAll">Food and Drug Administration. Information for Sponsor-Investigators Submitting Investigational New Drug Applications (INDs): Form 1572. https://www.fda.gov/drugs/investigational-new-drug-ind-application/information-sponsor-investigators-submitting-investigational-new-drug-applications-inds#form1572 (Accessed on October 29, 2021).</li><li><a class="nounderline abstract_t">Ji B, Perani EG, Petinom C, Grosset JH. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother 1996; 40:393.</a></li><li><a class="nounderline abstract_t">Ji B, Jamet P, Perani EG, et al. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis 1993; 168:188.</a></li><li><a class="nounderline abstract_t">Pardillo FE, Burgos J, Fajardo TT, et al. Powerful bactericidal activity of moxifloxacin in human leprosy. Antimicrob Agents Chemother 2008; 52:3113.</a></li><li><a class="nounderline abstract_t">Pardillo FE, Burgos J, Fajardo TT, et al. Rapid killing of M. leprae by moxifloxacin in two patients with lepromatous leprosy. Lepr Rev 2009; 80:205.</a></li><li><a class="nounderline abstract_t">Kamath S, Vaccaro SA, Rea TH, Ochoa MT. Recognizing and managing the immunologic reactions in leprosy. J Am Acad Dermatol 2014; 71:795.</a></li><li><a class="nounderline abstract_t">Walker SL, Lockwood DN. Leprosy type 1 (reversal) reactions and their management. Lepr Rev 2008; 79:372.</a></li><li><a class="nounderline abstract_t">Maymone MBC, Venkatesh S, Laughter M, et al. Leprosy: Treatment and management of complications. J Am Acad Dermatol 2020; 83:17.</a></li><li><a class="nounderline abstract_t">Van Veen NH, Nicholls PG, Smith WC, Richardus JH. Corticosteroids for treating nerve damage in leprosy. Cochrane Database Syst Rev 2016; 2016:CD005491.</a></li><li><a class="nounderline abstract_t">Rao PS, Sugamaran DS, Richard J, Smith WC. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev 2006; 77:25.</a></li><li><a class="nounderline abstract_t">Wagenaar I, Post E, Brandsma W, et al. Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial. PLoS Negl Trop Dis 2017; 11:e0005952.</a></li><li><a class="nounderline abstract_t">Van Veen NH, Lockwood DN, Van Brakel WH, et al. Interventions for erythema nodosum leprosum. A Cochrane review. Lepr Rev 2009; 80:355.</a></li><li><a class="nounderline abstract_t">Smith WC, Anderson AM, Withington SG, et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ 2004; 328:1459.</a></li><li><a class="nounderline abstract_t">Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev 2006; 19:338.</a></li><li><a class="nounderline abstract_t">Marlowe SN, Leekassa R, Bizuneh E, et al. Response to ciclosporin treatment in Ethiopian and Nepali patients with severe leprosy Type 1 reactions. Trans R Soc Trop Med Hyg 2007; 101:1004.</a></li><li><a class="nounderline abstract_t">Sena CB, Salgado CG, Tavares CM, et al. Cyclosporine A treatment of leprosy patients with chronic neuritis is associated with pain control and reduction in antibodies against nerve growth factor. Lepr Rev 2006; 77:121.</a></li><li><a class="nounderline abstract_t">Jaume L, Hau E, Monsel G, et al. Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study. PLoS Negl Trop Dis 2023; 17:e0011238.</a></li><li><a class="nounderline abstract_t">Nabarro LEB, Aggarwal D, Armstrong M, et al. The use of steroids and thalidomide in the management of Erythema Nodosum Leprosum; 17 years at the Hospital for Tropical Diseases, London. Leprosy Review 2016; 87:221.</a></li><li><a class="nounderline abstract_t">Upputuri B, Pallapati MS, Tarwater P, Srikantam A. Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India. PLoS Negl Trop Dis 2020; 14:e0008678.</a></li><li><a class="nounderline abstract_t">Perez-Molina JA, Arce-Garcia O, Chamorro-Tojeiro S, et al. Use of methotrexate for leprosy reactions. Experience of a referral center and systematic review of the literature. Travel Med Infect Dis 2020; 37:101670.</a></li><li><a class="nounderline abstract_t">Bedoui Y, Guillot X, Sélambarom J, et al. Methotrexate an Old Drug with New Tricks. Int J Mol Sci 2019; 20.</a></li><li><a class="nounderline abstract_t">de Barros B, Lambert SM, Shah M, et al. Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial. BMJ Open 2020; 10:e037700.</a></li><li><a class="nounderline abstract_t">Jopling WH. Complications of treatment with clofazimine (Lamprene: B663). Lepr Rev 1976; 47:1.</a></li><li><a class="nounderline abstract_t">Mendes AFM, Gomes CM, Kurizky PS, Ianhez M. Case Report: A Case Series of Immunobiological Therapy (Anti-TNF-α) for Patients With Erythema Nodosum Leprosum. Front Med (Lausanne) 2022; 9:879527.</a></li><li><a class="nounderline abstract_t">Cogen AL, Lebas E, De Barros B, et al. Biologics in Leprosy: A Systematic Review and Case Report. Am J Trop Med Hyg 2020; 102:1131.</a></li><li class="breakAll">Stryjewska B, personal communication.</li><li><a class="nounderline abstract_t">Rea TH, Jerskey RS. Clinical and histologic variations among thirty patients with Lucio's phenomenon and pure and primitive diffuse lepromatosis (Latapi's lepromatosis). Int J Lepr Other Mycobact Dis 2005; 73:169.</a></li><li><a class="nounderline abstract_t">Fajardo TT, Villahermosa L, Pardillo FE, et al. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens. Am J Trop Med Hyg 2009; 81:330.</a></li><li><a class="nounderline abstract_t">Gelber RH, Balagon VF, Cellona RV. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis 2004; 72:493.</a></li><li><a class="nounderline abstract_t">RIDLEY DS. Therapeutic trials in leprosy using serial biopsies. Lepr Rev 1958; 29:45.</a></li><li class="breakAll">Enhanced global strategy for further reducing the disease burden due to leprosy, 2011-2015. SEA-GLP-2209.4, World Health Organization; WHO Regional Office for SE Asia, New Delhi, 2009.</li><li><a class="nounderline abstract_t">Williams DL, Lewis C, Sandoval FG, et al. Drug resistance in patients with leprosy in the United States. Clin Infect Dis 2014; 58:72.</a></li><li><a class="nounderline abstract_t">Cambau E, Saunderson P, Matsuoka M, et al. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15. Clin Microbiol Infect 2018; 24:1305.</a></li><li><a class="nounderline abstract_t">Martiniuk F, Rao SD, Rea TH, et al. Leprosy as immune reconstitution inflammatory syndrome in HIV-positive persons. Emerg Infect Dis 2007; 13:1438.</a></li><li><a class="nounderline abstract_t">Lawn SD, Lockwood DN. Leprosy after starting antiretroviral treatment. BMJ 2007; 334:217.</a></li><li><a class="nounderline abstract_t">Lockwood DN, Lambert SM. Human immunodeficiency virus and leprosy: an update. Dermatol Clin 2011; 29:125.</a></li><li><a class="nounderline abstract_t">Duncan ME. An historical and clinical review of the interaction of leprosy and pregnancy: a cycle to be broken. Soc Sci Med 1993; 37:457.</a></li><li><a class="nounderline abstract_t">Lockwood DN, Sinha HH. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis 1999; 67:6.</a></li><li><a class="nounderline abstract_t">Saunderson P, Gebre S, Desta K, Byass P. The ALERT MDT Field Evaluation Study (AMFES): a descriptive study of leprosy in Ethiopia. Patients, methods and baseline characteristics. Lepr Rev 2000; 71:273.</a></li><li><a class="nounderline abstract_t">Maurus JN. Hansen's disease in pregnancy. Obstet Gynecol 1978; 52:22.</a></li><li><a class="nounderline abstract_t">Duncan ME, Pearson JM. The association of pregnancy and leprosy--III. Erythema nodosum leprosum in pregnancy and lactation. Lepr Rev 1984; 55:129.</a></li><li><a class="nounderline abstract_t">Wang L, Wang H, Yan L, et al. Single-Dose Rifapentine in Household Contacts of Patients with Leprosy. N Engl J Med 2023; 388:1843.</a></li><li><a class="nounderline abstract_t">Shen J, Wang Y, Zhou M, Li W. Analysis on value of household contact survey in case detection of leprosy at a low endemic situation in China. Indian J Dermatol Venereol Leprol 2009; 75:152.</a></li><li class="breakAll">World Health Organization. Leprosy/Hansen disease: Contact tracing and post-exposure prophylaxis. Technical guidance. ISBN: 978 92 9022 807 3. https://www.who.int/publications/i/item/9789290228073 (Accessed on June 30, 2023).</li><li><a class="nounderline abstract_t">Moet FJ, Pahan D, Oskam L, et al. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ 2008; 336:761.</a></li><li><a class="nounderline abstract_t">Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996; 348:17.</a></li><li><a class="nounderline abstract_t">Bertolli J, Pangi C, Frerichs R, Halloran ME. A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar. Int J Epidemiol 1997; 26:888.</a></li><li><a class="nounderline abstract_t">Düppre NC, Camacho LA, da Cunha SS, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg 2008; 102:631.</a></li><li><a class="nounderline abstract_t">Gillis T. Is there a role for a vaccine in leprosy control? Lepr Rev 2007; 78:338.</a></li></ol></div><div id="topicVersionRevision">Topic 16520 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://apps.who.int/iris/bitstream/handle/10665/274127/9789290226383-eng.pdf?ua=1" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy. https://apps.who.int/iris/bitstream/handle/10665/274127/9789290226383-eng.pdf?ua=1 (Accessed on June 10, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.hrsa.gov/sites/default/files/hrsa/hansens-disease/hansens-disease-guide-management.pdf" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : NHDP Guide to the Management of Hansen's disease https://www.hrsa.gov/sites/default/files/hrsa/hansens-disease/hansens-disease-guide-management.pdf.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : World Health Organization. Leprosy/Hansen Disease: Management of reactions and prevention of disabilities, Dr E. A. Cooreman (Ed), WHO Technical Guidance, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25831531" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Insight into the evolution and origin of leprosy bacilli from the genome sequence of Mycobacterium lepromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633074" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21941157" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Evaluation of multi-drug therapy for leprosy in the United States using daily rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6806990" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chemotherapy of leprosy for control programmes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6806990" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chemotherapy of leprosy for control programmes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20830851" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Global leprosy situation, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11395918" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Leprosy. Global target attained.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11395918" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Leprosy. Global target attained.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11395918" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Leprosy. Global target attained.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9715593" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Why multidrug therapy for multibacillary leprosy can be shortened to 12 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561134" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Malta Project--a country freed itself of leprosy. A 27-year progress study (1972-1999) of the first successful eradication of leprosy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27402522" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Two Cases of Leprosy in Siblings Caused by Mycobacterium lepromatosis and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27430540" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Infection with Mycobacterium lepromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27430540" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Infection with Mycobacterium lepromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/804443" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Susceptibility of thymectomized and irradiated mice to challenge with several organisms and the effect of dapsone on infection with Mycobacterium leprae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/772686" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of rifampin, clofazimine, and B1912 on the viability of Mycobacterium leprae in established mouse footpad infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2694952" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2694952" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2071982" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929269" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : In vitro activities of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16707521" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Incidence of ocular complications in patients with multibacillary leprosy after completion of a 2 year course of multidrug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25071003" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36145477" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36145477" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8834886" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8257487" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18573938" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Powerful bactericidal activity of moxifloxacin in human leprosy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19743625" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rapid killing of M. leprae by moxifloxacin in two patients with lepromatous leprosy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24767732" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recognizing and managing the immunologic reactions in leprosy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19274984" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Leprosy type 1 (reversal) reactions and their management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32244016" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Leprosy: Treatment and management of complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27210895" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Corticosteroids for treating nerve damage in leprosy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16715687" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28976976" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20306635" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Interventions for erythema nodosum leprosum. A Cochrane review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159285" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16614253" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The continuing challenges of leprosy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17669450" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Response to ciclosporin treatment in Ethiopian and Nepali patients with severe leprosy Type 1 reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16895068" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cyclosporine A treatment of leprosy patients with chronic neuritis is associated with pain control and reduction in antibodies against nerve growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37079647" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The use of steroids and thalidomide in the management of Erythema Nodosum Leprosum; 17 years at the Hospital for Tropical Diseases, London</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33035210" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32302727" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Use of methotrexate for leprosy reactions. Experience of a referral center and systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31658782" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Methotrexate an Old Drug with New Tricks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33203627" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1263731" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Complications of treatment with clofazimine (Lamprene: B663).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35814767" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Case Report: A Case Series of Immunobiological Therapy (Anti-TNF-α) for Patients With Erythema Nodosum Leprosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32157993" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Biologics in Leprosy: A Systematic Review and Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32157993" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Biologics in Leprosy: A Systematic Review and Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16830639" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical and histologic variations among thirty patients with Lucio's phenomenon and pure and primitive diffuse lepromatosis (Latapi's lepromatosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19635893" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755209" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13515393" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Therapeutic trials in leprosy using serial biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13515393" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Therapeutic trials in leprosy using serial biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24065328" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Drug resistance in patients with leprosy in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29496597" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18252138" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Leprosy as immune reconstitution inflammatory syndrome in HIV-positive persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17272530" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Leprosy after starting antiretroviral treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21095536" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Human immunodeficiency virus and leprosy: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8211258" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : An historical and clinical review of the interaction of leprosy and pregnancy: a cycle to be broken.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10407623" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pregnancy and leprosy: a comprehensive literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11105487" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The ALERT MDT Field Evaluation Study (AMFES): a descriptive study of leprosy in Ethiopia. Patients, methods and baseline characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/683625" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hansen's disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6748844" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The association of pregnancy and leprosy--III. Erythema nodosum leprosum in pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37195940" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Single-Dose Rifapentine in Household Contacts of Patients with Leprosy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293502" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Analysis on value of household contact survey in case detection of leprosy at a low endemic situation in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293502" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Analysis on value of household contact survey in case detection of leprosy at a low endemic situation in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18332051" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8691924" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9279624" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18514242" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Effectiveness of BCG vaccination among leprosy contacts: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18309707" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Is there a role for a vaccine in leprosy control?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
